Amylyx Pharmaceuticals, Inc. (AMLX) Free cash flow 2021–2025
Amylyx Pharmaceuticals, Inc. (AMLX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$123.5MFY2025 · since FY2021: -$75.2M → -$123.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$123.5M | +26.4% |
| FY2024 | -$167.8M | -1671.5% |
| FY2023 | $10.7M | +105.9% |
| FY2022 | -$182.4M | -142.7% |
| FY2021 | -$75.2M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More AMLX financial trends
AMLX RevenueAMLX Net incomeAMLX Net marginAMLX Gross profitAMLX Gross marginAMLX Operating incomeAMLX Operating marginAMLX Operating cash flowAMLX Capital expendituresAMLX Return on equityAMLX Stock buybacksAMLX Dividends paidAMLX Total assetsAMLX Total liabilitiesAMLX Shareholders’ equityAMLX overview →